Pharmesis International Ltd
SGX:BFK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (0.8), the stock would be worth S$0.17 (52% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.6 | S$0.36 |
0%
|
| 3-Year Average | 0.8 | S$0.17 |
-52%
|
| 5-Year Average | 0.4 | S$0.08 |
-77%
|
| Industry Average | 3.5 | S$0.76 |
+114%
|
| Country Average | 3.3 | S$0.72 |
+102%
|
Forward EV/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
P
|
Pharmesis International Ltd
SGX:BFK
|
11.3m SGD | 1.6 | -14.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
825.8B USD | 12.9 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
548.5B USD | 6 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.6B GBP | 5.1 | 27.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF | 5.1 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.3B USD | 4.7 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 108.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 4 | 11.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 3.2 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.3B USD | 3.1 | 16.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.7 |
| Median | 3.3 |
| 70th Percentile | 6.2 |
| Max | 5 034 353.9 |
Other Multiples
Pharmesis International Ltd
Glance View
Pharmesis International Ltd. is an investment holding company, which engages in the research, development, production, sale, and marketing of medicine and medicine formulated products for the treatment of illnesses relating to the liver and gall bladder. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2004-10-06. The firm is a pharmaceutical company engaged in the manufacturing of pharmaceutical products, including western medicine in the form of tablets and granules, among others, and traditional Chinese medicine (TCM) formulated products for the treatment of illnesses relating to the liver and gall bladder. The company operates in three segments: Western drugs, which refers mainly to chemically formulated drugs marketed under the Kinna brand; TCM formulated drugs, which includes TCM marketed under the Longlife brand, and Distribution, which includes agency products and internally manufactured products marketed through the distribution arm. Its main products are ATT, Gulin Gansu and Er Ding granules. Its subsidiary, Chengdu Kinna Pharmaceutical Co., Ltd, is engaged in the development, manufacture, packaging and sale of western medicines and health tonic products.
